VRPX - Virpax Pharmaceuticals, Inc. Total Debt to Capital

This chart of market price action for the total debt-to-equity ratio of Virpax Pharmaceuticals (VRPX) is 0.00. Virpax Pharmaceuticals is developing scientific partnerships with defense agencies to create new analgesics. The strategy is based on implementing nasal drug delivery methods to the brain to expand into the psychopharmaceuticals segment. Medium-term prospects rely on the development of platforms to combat acute pain and the optimization of internal costs.

Cash deficits and internal management conflicts at Virpax Pharmaceuticals (VRPX) are limiting investment inflows, forcing the biotech firm to gradually deplete its existing reserves. Analyzing the liability structure—specifically total debt to equity—an investor can determine the proportion of borrowed capital per unit of equity, allowing for an assessment of the financial leverage and bankruptcy risk associated with this high-risk asset.